Compare Amgen, Inc. (AMGN) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs VanEck Semiconductor ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while VanEck Semiconductor ETF trades at $599.5. The key difference: Amgen, Inc. pays a 2.77% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals.
| AMGN | SMH | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $668.91 |
52-Week Low | $271.18 | $283.95 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SMH trades at $611.40, up 0.6% with a neutral technical signal. Recent news highlights strong 2026 performance, including a 64% YTD gain and 113% over 12 months, driven by semiconductor sector trends and AI infrastructure demand. However, the ETF faced a 13% pullback from recent highs amid broader chip stock volatility, with key support at $602 and resistance at $616.
Outlook remains positive due to AI-driven semiconductor demand, but risks include sector concentration, geopolitical tensions, and potential rotation away from chip stocks. JPMorgan recommends buying the dip, while Morgan Stanley notes a possible shift to hyperscalers, indicating cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
